Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.

BACKGROUND The role of neurohormonal inhibition in chronic heart failure is well established. There is limited data on the effect of up-titration of renin angiotensin inhibition (RASi) and beta-blockers (BBs) on clinical outcomes of patients with worsening heart failure (HF) across the left ventricular ejection fraction (LVEF) spectrum. METHODS AND RESULTS We analyzed data from 2345 patients from BIOSTAT-CHF (80.9% LVEF<40%), who completed a 3-month up-titration period after recent worsening of HF. Patients were classified by achieved dose (% of recommended): ≥100%, 50%-99%, 1%-49%, and none. Recurrent event analysis using joint and shared frailty models was used to examine the association between RASi/BBs dose and all-cause and HF hospitalizations. In the 21-months following up-titration, 512 patients died and 879 (37.5%) had ≥1 hospitalization. RASi up-titration was associated, incrementally, with reduced risk of all-cause hospitalization at all achieved dose-levels compared to no treatment [HR (95%CI): ≥100%: 0.60(0.49-0.74), p < 0.001; 50%-99%: 0.56(0.46-0.68), p < 0.001; 1%-49%: 0.71(0.59-0.86), p < 0.001]. This association was consistent up to an LVEF of 49% (p < 0.001), and when considering only HF hospitalizations. Up-titration of BBs was associated with fewer all-cause hospitalizations only when LVEF was <40% (overall p < 0.001), but with more HF hospitalizations when LVEF was ≥50%. Up-titration of both RASi/BBs was associated with lower mortality in LVEF up to 49%. CONCLUSION After recent worsening of HF, up-titration of RASi and BBs was associated with a better prognosis in patients with LVEF ≤49%. Up-titration of BBs was associated with a greater risk of HF hospitalization when LVEF was ≥50%. This article is protected by copyright. All rights reserved.